Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THERAMAG
2024-516335-27-00Phase 3Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in anti-myelin-associated glycoprotein neuropathy, sponsored by CHU Saint-Etienne. Primary endpoint: Clinical response measured by I-RODS. Planned start Oct 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on 2024-516335-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516335-27-00.